LI
AVXL icon

Leap Investments’s Anavex Life Sciences AVXL Stock Holding History

Leap Investments’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-24,136
Closed -$63K – 370
2019
Q4 		$63K Buy
+24,136
New +$63.4K 0.03% 394

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Leap Investments's AVXL Position: Q1 2020 in Review

Leap Investments sold out of Anavex Life Sciences (AVXL) in Q1 2020, closing a stake of 24,136 shares — an estimated $63K sold.

Leap Investments first reported a position in AVXL in Q4 2019 and held it in 1 quarter. The position peaked at $63K in Q4 2019. 70 funds tracked by Wall St. Rank hold AVXL as of Q1 2020.

  • Leap Investments reported no remaining Anavex Life Sciences position as of Q1 2020 after selling out during the quarter.
  • Leap Investments sold 24,136 Anavex Life Sciences shares in Q1 2020, an estimated $63K.
  • Leap Investments first reported a position in Anavex Life Sciences in Q4 2019 and held it in 1 quarter.
  • Leap Investments's Anavex Life Sciences position peaked at $63K in Q4 2019.
  • 70 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.